CIPLA LTD vs NOVARTIS INDIA LIMITED

A side-by-side comparison of CIPLA LTD (CIPLA) and NOVARTIS INDIA LIMITED (NOVARTIND) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs NOVARTIND on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
38.42
3.42
P/B ratio
4.41
0.90%
Dividend yield
1.70%
₹48.02
EPS
₹40.87

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
12.85%
15.00%
Return on capital
17.00%
21.00%
EBITDA margin
26.00%
13.71%
Net margin
28.37%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
-2.22%
10.88%
Profit CAGR (3Y)
-3.28%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹3,880 Cr
₹28,163 Cr
Revenue
₹356 Cr
₹3,862 Cr
Net profit
₹101 Cr
0.02
Debt / equity
0.00
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
NOVARTIS INDIA LIMITED
  • + ["Company has reduced debt.", "Company is almost debt free."]
  • ["The company has delivered a poor sales growth of -1.46% over past five years.", "Company has a low return on equity of 11.9% over last 3 years.", "Earnings include an other income of Rs.38.8 Cr."]
CIPLA LTD full analysis NOVARTIS INDIA LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.